Xvivo Perfusion AB (ST:XVIVO) — Stock Price

Skr281.00 SEK
▲ 0.86% today

Xvivo Perfusion AB (ST:XVIVO) is currently trading at Skr281.00 SEK, up 0.86% today. Over the past 52 weeks, shares have ranged between Skr160.80 and Skr305.20. This page tracks Xvivo Perfusion AB's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Xvivo Perfusion AB market capitalisation.

Xvivo Perfusion AB (XVIVO) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Xvivo Perfusion AB's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.

Xvivo Perfusion AB Income Statement — Revenue, Profit & Earnings by Year

Xvivo Perfusion AB's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue Skr812.16 Million Skr822.41 Million Skr597.54 Million Skr415.29 Million Skr258.39 Million
Cost of Revenue Skr278.67 Million Skr206.00 Million Skr152.43 Million Skr118.34 Million Skr70.11 Million
Gross Profit Skr533.50 Million Skr616.41 Million Skr445.11 Million Skr296.96 Million Skr188.28 Million
Research & Development Skr100.69 Million Skr148.33 Million Skr135.94 Million Skr69.34 Million Skr54.04 Million
SG&A Skr78.14 Million Skr95.79 Million Skr76.94 Million Skr70.98 Million Skr55.69 Million
Total Operating Expenses Skr440.48 Million Skr528.06 Million Skr440.92 Million Skr292.50 Million Skr207.02 Million
Operating Income Skr93.02 Million Skr88.35 Million Skr4.19 Million Skr23.18 Million Skr6.98 Million
EBITDA Skr153.14 Million Skr272.97 Million Skr35.05 Million Skr39.21 Million Skr39.20 Million
EBIT Skr82.93 Million Skr205.55 Million Skr4.19 Million Skr23.41 Million Skr6.94 Million
Interest Expense Skr44.37 Million Skr5.60 Million Skr1.19 Million Skr1.09 Million Skr276.00K
Income Before Tax Skr38.56 Million Skr199.95 Million Skr94.52 Million Skr22.31 Million Skr6.67 Million
Income Tax Expense Skr13.40 Million Skr27.77 Million Skr2.70 Million Skr3.89 Million Skr-1.49 Million
Net Income Skr25.16 Million Skr172.18 Million Skr91.82 Million Skr18.43 Million Skr8.15 Million

Xvivo Perfusion AB Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Xvivo Perfusion AB's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets Skr2.37 Billion Skr2.40 Billion Skr2.20 Billion Skr1.73 Billion Skr1.54 Billion
Total Current Assets Skr688.21 Million Skr813.08 Million Skr826.40 Million Skr467.51 Million Skr547.53 Million
Cash & Equivalents Skr292.09 Million Skr415.22 Million Skr546.09 Million Skr246.54 Million Skr398.70 Million
Short-term Investments — Skr0.00 Skr300.00 Million Skr71.31 Million —
Net Receivables Skr147.66 Million Skr132.12 Million Skr98.13 Million Skr99.82 Million Skr59.62 Million
Inventory Skr248.46 Million Skr227.41 Million Skr141.60 Million Skr106.57 Million Skr77.59 Million
Property, Plant & Equipment Skr213.88 Million Skr149.04 Million Skr97.55 Million Skr47.58 Million Skr26.30 Million
Goodwill Skr610.06 Million Skr682.48 Million Skr591.39 Million Skr625.32 Million Skr460.23 Million
Total Liabilities Skr260.65 Million Skr245.97 Million Skr250.57 Million Skr302.95 Million Skr257.15 Million
Total Current Liabilities Skr119.38 Million Skr177.51 Million Skr134.49 Million Skr134.90 Million Skr104.52 Million
Long-term Debt Skr83.27 Million — — Skr4.46 Million Skr1.52 Million
Net Debt Skr-54.20 Million Skr-381.48 Million Skr-514.35 Million Skr-236.54 Million Skr-392.98 Million
Total Stockholder Equity Skr2.11 Billion Skr2.16 Billion Skr1.95 Billion Skr1.43 Billion Skr1.29 Billion
Retained Earnings Skr316.90 Million Skr291.75 Million Skr119.57 Million Skr27.75 Million Skr9.28 Million

Xvivo Perfusion AB Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Xvivo Perfusion AB generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow Skr101.07 Million Skr111.29 Million Skr46.29 Million Skr27.86 Million Skr-12.06 Million
Capital Expenditures Skr101.07 Million Skr193.15 Million Skr43.02 Million Skr130.95 Million Skr94.07 Million
Free Cash Flow Skr101.07 Million Skr-81.86 Million Skr-97.65 Million Skr-103.09 Million Skr-106.13 Million
Investing Cash Flow Skr-258.41 Million Skr-243.81 Million Skr-161.62 Million Skr-197.62 Million Skr-187.70 Million
Financing Cash Flow Skr72.25 Million Skr-10.90 Million Skr418.55 Million Skr-6.84 Million Skr234.61 Million
Dividends Paid — — — Skr7.29 Million —
Stock-Based Compensation Skr14.41 Million Skr6.57 Million Skr2.30 Million Skr6.69 Million Skr2.60 Million
Depreciation Skr70.21 Million Skr87.72 Million Skr30.86 Million Skr42.17 Million Skr32.26 Million
Change in Cash Skr-123.43 Million Skr-130.57 Million Skr299.54 Million Skr-152.15 Million Skr44.46 Million

Xvivo Perfusion AB Earnings History — EPS Actual vs. Analyst Estimates

Track Xvivo Perfusion AB's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Jul 14, 2026 — 1.07 —
Apr 24, 2026 1.15 1.34 -14.18%
Jan 27, 2026 1.01 -12.65 +107.98%
Oct 23, 2025 0.14 0.40 -65.00%
Jul 11, 2025 0.04 0.63 -93.65%
Apr 24, 2025 -0.30 0.91 -132.97%
Jan 28, 2025 1.64 0.80 +105.00%
Oct 24, 2024 2.86 0.80 +257.50%